Randomized trial · people

PT-141: more responders than placebo at 1.75 mg on all 7 measures

Checked against the paper Randomized trialPublished by PepVault

The takeaway

This paper set the bar for what counts as a real response to bremelanotide in women with low desire, found the 1.75 mg dose cleared it more often than placebo, and supplied the response definitions later used in the RECONNECT phase 3 studies.

Kind
Randomized trial
Studied in
People
Published
2019
Journal
J Sex Med

What they tested

The team wanted to set the smallest change in sexual function scores that patients would find meaningful, then use that cutoff to see how many women responded to bremelanotide (PT-141) versus placebo.

How the study was done

A randomized, placebo-controlled, dose-finding phase 2b trial in premenopausal women with hypoactive sexual desire disorder (HSDD, low sexual desire), with or without female sexual arousal disorder (FSAD). Seven questionnaire-based endpoints were checked with up to 4 kinds of responder analysis, some planned and some post hoc (decided after the data came in).

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking PT-141? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

Cutoffs for a meaningful change, worked out from the trial's own data, lined up with the cutoffs clinical experts had estimated. On all 7 endpoints, the 1.75 mg arm had a statistically significant higher share of responders than placebo in the main analysis group. The team reported bremelanotide was safe and well tolerated in this trial.

What it doesn’t show

Only premenopausal women diagnosed with HSDD and/or FSAD were studied, so the results may not apply to other people. The meaningful-change cutoffs came from the same trial they were used to judge, and some of the analyses were post hoc.

The paper

Althof et al. Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide. J Sex Med. 2019.

The compound

More studies on PT-141

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking PT-141? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo